A 17-year-old Girl with a Neck Mass
Robert Listernick, MD T his 17-year-old girl was seen for evaluation of a neck mass. She had been well until 1 week before this outpatient visit, when she described pain in her neck behind her right ear, followed by the development of a lump in the front of her neck. There was no history of dysphagia or other symptoms.
Her past medical history was remarkable. She had had a primitive neuroectodermal tumor (PNET) of her posterior fossa, which was diagnosed at 6 years. After surgical removal, she received chemotherapy and radiation therapy to the head and neck, and she has had no recurrence of the tumor. In addition, the family history is remarkable in that her mother has some form of cystic kidney disease. She had undergone hemodialysis for the past 2 years. The patient's brother, at 15 years, was said to have "abnormal kidney function." The patient was told at some point in her life that she had "cysts on her kidneys." The maternal grandmother also has cystic kidney disease.
On exam, she appeared well and was in no distress. Her weight was in the 10th percentile, and her height was less than the fi fth percentile. Pulse was 88, blood pressure 125/82. Physical examination was unremarkable except for a diffusely enlarged nontender thyroid gland. There was a 3-cm palpable mass overlying the suprasternal notch.
On laboratory testing, free T4 and TSH were normal. BUN was 32 mg/dL, and creatinine 1.3 mg/ dL. Urinalysis was normal.
Robert Listernick, MD, moderator: What's a PNET?
Jason Fangusaro, MD, pediatric oncologist: The literature is confusing. As of 2010, a posterior fossa PNET is now called a medulloblastoma, the most common malignant pediatric brain tumor. The family history is remarkable in that her mother has some form of cystic kidney disease.
Dr. Listernick:
In addition, children who are homozygous or compound heterozygotes for one of four DNA mismatch repair genes are at risk for the development of café-au-lait spots, adenomatous colonic polyps, medulloblastoma, glioblastoma, and ependymoma. They also may develop leukemia and lymphoma.
Dr. Fangusaro: Still, the majority of medulloblastomas are sporadic and not associated with any of these syndromes.
Dr. Listernick: We don't have details, but what treatment would you suspect she received 12 years ago?
Dr. Fangusaro: She most likely received a combination of chemotherapy and a radiation dose of 3,600 Gy to the craniospinal axis, with boost to the posterior fossa. We have found that it's important to irradiate the spinal cord, even if there's no evidence of disease to prevent recurrences. Currently, in patients who have isolated medulloblastoma and no high-risk features, we are using lower doses of radiation and achieving close to 85% to 90% at 5-year overall survival. If the patient is younger (typically younger than 3 years), or if there's residual disease or anaplastic histology, the 5-year overall survival is closer to 50% to 60%. Don Zimmerman, MD, pediatric endocrinologist: It's worth noting that her extreme short stature is most likely related to the craniospinal irradiation through two possible mechanisms -either a direct adverse effect on vertebral column growth or due to the development of growth-hormone defi ciency.
Dr. Listernick: Let's discuss the potential long-term effects of her cancer treatment.
Kim Dilley, MD, general academic pediatrician: Radiation is obviously the biggest factor in creating late effects of cancer treatment, particularly in the generation of second malignancies. Radiation exposure to the pituitary or thyroid glands may lead to growth failure. The combination of cyclophosphamide and radiation could have profound effects on fertility, whereas the combination of radiation and a platinum-containing drug might very well cause hearing loss. The most common solid tumors following radiation exposure include thyroid cancer and soft tissue sarcomas. An interesting phenomenon is that the risk of thyroid cancer increases up to 30 Gy of exposure; if the radiation dose is higher, the risk of malignancy signifi cantly deceases probably as a result of cell death. Finally, neurocognitive long-term effects can be a huge burden on this population.
Dr. Fangusaro: Modern techniques, such as proton beam radiation, can target a lesion more effectively, minimizing radiation scatter.
Dr. Listernick: Let's talk about the family history of cystic kidney disease.
Richard Cohn, MD, pediatric kidney diseases specialist: There are three big categories of cystic kidney diseases: simple cysts, acquired cystic diseases, and autosomal dominant polycystic kidney disease (ADPKD Dr. Cohn: There has been a study in adults using a class of medications called the vaptans, which are ADH-receptor antagonists. Preliminarily, these medications may delay the progression of cyst development by infl uencing the amount of fl uid that enters the cysts. Eventually, early diagnosis of ADPKD may be essential for preventing subsequent kidney failure. Presently, many families eschew early diagnostic testing for fear of not being able to obtain health insurance.
Dr. Listernick: If you had been treating her PNET and had known that she had ADPKD, would that have changed your approach and not used any drugs which had potential nephrotoxicity? Dr. Fangusaro: That's a diffi cult question, but probably not. Our fi rst goal would have been to effectively treat her brain tumor. Of course, monitoring renal function carefully is part of any child's treatment.
Dr. Listernick: Let's talk about the thyroid mass.
Erin Rowell, MD, pediatric surgeon: She had a 3-cm central thyroid nodule that felt cystic, and the thyroid gland was diffusely enlarged and fi rm. Given the entire scenario, I was fairly convinced that she had a malignancy and that she needed a total thyroidectomy. Dr. Listernick: Why perform an ultrasound if you were going to perform a thyroidectomy regardless of the results? Dr. Rowell: I wanted to see the surrounding tissue and to see if there was signifi cant adenopathy that might represent spread of disease. I can also use the images to help explain the surgery to the family.
Dr. Listernick: What about a fi ne needle biopsy? Dr. Rowell: Given the high likelihood of cancer in this patient with her history of radiation therapy and the diffusely enlarged gland, a negative result might be a sampling error and wouldn't have prevented me from recommending total thyroidectomy. Dr. Saker: Ultrasonography revealed a diffusely enlarged gland with heterogeneous echogenicity and multiple cysts throughout. There was concern for metastatic disease within the gland.
Dr. Dilley: I should mention that there is a theory that stimulation by a minimally elevated TSH may predispose long-term survivors to the development of cancer. Although it's far from proven, some physicians who care for long-term cancer survivors who have received thyroid irradiation treat their patients with Synthroid to prevent this from happening.
Dr. Rowell: The surgery went smoothly. We carefully monitored the recurrent laryngeal nerves to prevent damage. They may be diffi cult to preserve in a diffusely enlarged malignant gland. All the parathyroid glands were identifi ed and preserved. Because they had also been exposed to radiation, I wanted to make sure that there was no suspicion of malignancy. Finally, I performed a central compart-ment lymphadenectomy in which I tried to take the fatty tissue that is over the sternal notch and pull up the thymic remnants from the mediastinum to remove all the attached lymph nodes.
Dr. Listernick: Let's see the pathology.
Elaine Cham, MD, pediatric pathologist: The lesion has proven to be very diffi cult to classify. Both lobes were diffusely enlarged. In the left lobe, there appears to be a nodule with an ill-defi ned capsule. Sections of the thyroid are markedly cellular with a sclerotic stroma in between. We didn't see the nuclear features needed for establishing the diagnosis of papillary thyroid carcinoma. The differential diagnosis includes nodular hyperplasia and follicular neoplasms, either follicular adenoma or follicular carcinoma. The latter should have a very well-defi ned capsule. Follicular neoplasms should be solitary, whereas this lesion is multifocal.
Dr. Listernick: How do you distinguish between follicular adenoma and follicular carcinoma?
Dr. Cham: The only way to tell the difference between the two is by seeing vascular or capsular invasion or evidence of extrathyroidal extension or distal metastasis. Cytologically, they are basically identical.
Dr. Listernick: So either it's benign, cancer, or a really bad cancer.
Dr. Cham:
We're concerned about the marked hypercellularity that has been described in nodular hyperplasia. However, the hypercellularity in that condition is generally focal rather than diffuse as it is here. There's a suggestion on some sections of capsular invasion, and we continue to look for further signs with special stains.
Dr. Zimmerman: I suspect this will turn out to be follicular carcinoma, given what we know so far. Interestingly, most of the radiation-induced carcinomas are papillary. She will certainly require a radioiodine nuclear scan looking for metastases. If this turns out to be angioinvasive follicular carcinoma, she will require radioiodine treatment, and the prognosis is not so good.
Dr. Listernick: Thank you, everybody.
fi rm rounds
She will certainly require a radioiodine nuclear scan looking for metastases.
